Profibrinolytic properties characterize a stably transformed human endothelial cell line

被引:4
作者
Camera, M
Hajjar, KA
Pan, S
Szabo, P
Vicart, P
Paulin, D
Weksler, BB
机构
[1] Cornell Univ Med Coll, Dept Pediat, Div Hematol Oncol, New York, NY 10021 USA
[2] Cornell Univ Med Coll, Dept Med, Div Geriatr, New York, NY 10021 USA
[3] Inst Pasteur, SCME, F-75754 Paris, France
[4] Univ Paris 07, Lab Biol Mol Differenciat, F-75754 Paris, France
关键词
human endothelial cell line; fibrinolysis; plasminogen activators; plasminogen activator inhibitors; regulation;
D O I
10.1097/00001721-199803000-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A stable immortalized venous endothelial cell (IVEC) line, obtained by transfection of human umbilical vein endothelial cells (HUVEC), retains many normal differentiated endothelial characteristics. We compared the fibrinolytic activities of IVEC and HUVEC, and observed that IVEC express a more profibrinolytic phenotype than HUVEC, since they bind and activate plasminogen more efficiently, produce more tissue plasminogen activator and urokinase-type plasminogen activator antigens, and secrete less plasminogen activator inhibitor-1 antigen both under basal conditions and after stimulation with lipopolysaccharide, phorbol ester and tumor necrosis factor. Moreover, immunostaining and Western blotting of IVEC for the plasminogen/tissue plasminogen activator receptor annexin II, as well as Northern blotting of annexin II mRNA, revealed similar patterns of surface expression in IVEC and HUVEC. Plasminogen activator inhibitor-2 is expressed similarly in both cell types. IVEC may be a useful human model for functional and pharmacological explorations and modulations of fibrinolytic system components. (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 41 条
[1]   PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING [J].
ANDREASEN, PA ;
RICCIO, A ;
WELINDER, KG ;
DOUGLAS, R ;
SARTORIO, R ;
NIELSEN, LS ;
OPPENHEIMER, C ;
BLASI, F ;
DANO, K .
FEBS LETTERS, 1986, 209 (02) :213-218
[2]   IMMUNOLOGICAL IDENTIFICATION AND COMPARISON OF PLASMINOGEN-ACTIVATOR FORMS IN CULTURED NORMAL HUMAN-ENDOTHELIAL CELLS AND SMOOTH-MUSCLE CELLS [J].
BOOYSE, FM ;
SCHEINBUKS, J ;
RADEK, J ;
OSIKOWICZ, G ;
FEDER, S ;
QUARFOOT, AJ .
THROMBOSIS RESEARCH, 1981, 24 (5-6) :495-504
[3]  
BOOYSE FM, 1984, J BIOL CHEM, V259, P7198
[4]   PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE [J].
CARMELIET, P ;
SCHOONJANS, L ;
KIECKENS, L ;
REAM, B ;
DEGEN, J ;
BRONSON, R ;
DEVOS, R ;
VANDENOORD, JJ ;
COLLEN, D ;
MULLIGAN, RC .
NATURE, 1994, 368 (6470) :419-424
[5]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[6]  
COHEN RL, 1989, J BIOL CHEM, V264, P8375
[7]   GENERATION IN PLASMA OF A FAST-ACTING INHIBITOR OF PLASMINOGEN-ACTIVATOR IN RESPONSE TO ENDOTOXIN STIMULATION [J].
COLUCCI, M ;
PARAMO, JA ;
COLLEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) :818-824
[8]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[9]  
DICHEK D, 1989, BLOOD, V74, P222
[10]  
DURIEUTRAUTMANN O, 1991, IN VITRO CELL DEV B, V27, P771